Ovid Therapeutics Inc. Reports Q2 2026 Financial Results

What Happened
Ovid Therapeutics Inc. announced business updates and its second quarter 2026 financial results via a press release dated August 13, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02) filed with the SEC on August 13, 2026; the report was signed by Chief Financial Officer Charles Carter.

Key Details

• 8-K filed and press release furnished on August 13, 2026 (Exhibit 99.1).
• Item 2.02 relates to results of operations and financial condition (Q2 2026 results announced).
• Exhibit listing also includes the Inline XBRL cover page file (Item 9.01).
• Report signed by Charles Carter, Chief Financial Officer (dated August 13, 2026).

Why It Matters
This 8-K signals that Ovid has released its quarterly earnings and business updates; investors should review the furnished press release (Exhibit 99.1) for specific figures such as revenue, net income/loss, and any management commentary or guidance. The Form 8-K itself notifies the market that results are available—check the press release and subsequent filings for the detailed numbers and any impact on the company’s outlook.